<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01370629</url>
  </required_header>
  <id_info>
    <org_study_id>6621-049</org_study_id>
    <secondary_id>EP01029.004</secondary_id>
    <nct_id>NCT01370629</nct_id>
  </id_info>
  <brief_title>Study of Normal Conditions of Use, Dosing, and Safety of Intravenous (IV) Administration of Vernakalant (MK-6621-049)</brief_title>
  <official_title>A Prospective Observational Registry Study to Characterise Normal Conditions of Use, Dosing and Safety Following Administration of Vernakalant IV Sterile Concentrate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Correvio International Sarl</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Correvio International Sarl</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This non-interventional prospective study is a post-authorization safety study (PASS) of
      vernakalant conducted to collect information about normal conditions of use and appropriate
      dosing, and to quantify possible medically significant risks associated with the use of
      vernakalant in real-world clinical practice.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">May 8, 2018</completion_date>
  <primary_completion_date type="Actual">April 5, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Experiencing Significant Hypotension</measure>
    <time_frame>Start (baseline) of first vernakalant infusion up to 24 hours after the last infusion</time_frame>
    <description>Significant hypotension is defined as: symptomatic hypotension with systolic blood pressure (BP) &lt;90 mmHg, requiring treatment with vasopressors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Experiencing Significant Ventricular Arrhythmia</measure>
    <time_frame>Start (baseline) of first vernakalant infusion up to 24 hours after the last infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Experiencing Significant Atrial Flutter</measure>
    <time_frame>Start (baseline) of first vernakalant infusion up to 24 hours after the last infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Experiencing Significant Bradycardia</measure>
    <time_frame>Start (baseline) of first vernakalant infusion up to 24 hours after the last infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Are Converted to Sinus Rhythm for at Least One Minute</measure>
    <time_frame>Up to 90 minutes after the start (baseline) of first infusion of vernakalant</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">2015</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>All participants</arm_group_label>
    <description>Participants treated with vernakalant IV in acute care and inpatient hospital settings</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vernakalant</intervention_name>
    <description>Prescribed at the discretion of the physician in accordance with their usual practice</description>
    <arm_group_label>All participants</arm_group_label>
    <other_name>BRINAVESSÂ®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants treated with intravenous vernakalant in acute care and inpatient hospital
        settings per usual care
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  To be treated with intravenous vernakalant, independently of this study

          -  Participant and/or legal guardians willing to provide informed consent and/or informed
             assent according to local regulations

        Exclusion Criteria:

        - Enrollment in an investigational drug or device clinical trial in the 30 days prior to
        study enrolment. Participation in another non-interventional drug or device study or
        registry is permitted.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medizinische Universitat Wien</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kuopio Hospital</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St-Vincenz Krankenhaus</name>
      <address>
        <city>Paderborn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Severo Ochoa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skanes Universistetssjukhus</name>
      <address>
        <city>Malmo</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>Sweden</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>June 8, 2011</study_first_submitted>
  <study_first_submitted_qc>June 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2011</study_first_posted>
  <results_first_submitted>November 13, 2019</results_first_submitted>
  <results_first_submitted_qc>December 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 30, 2019</results_first_posted>
  <last_update_submitted>December 12, 2019</last_update_submitted>
  <last_update_submitted_qc>December 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>cardioversion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 3, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/29/NCT01370629/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 23, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/29/NCT01370629/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Participants</title>
          <description>Participants treated with vernakalant IV in acute care and inpatient hospital settings
Vernakalant: Prescribed at the discretion of the physician in accordance with their usual practice</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2015"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2009"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>Participants treated with vernakalant IV in acute care and inpatient hospital settings
Vernakalant: Prescribed at the discretion of the physician in accordance with their usual practice</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2009"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1024"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="985"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="787"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1931"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing Significant Hypotension</title>
        <description>Significant hypotension is defined as: symptomatic hypotension with systolic blood pressure (BP) &lt;90 mmHg, requiring treatment with vasopressors</description>
        <time_frame>Start (baseline) of first vernakalant infusion up to 24 hours after the last infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Participants treated with vernakalant IV in acute care and inpatient hospital settings
Vernakalant: Prescribed at the discretion of the physician in accordance with their usual practice</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Significant Hypotension</title>
          <description>Significant hypotension is defined as: symptomatic hypotension with systolic blood pressure (BP) &lt;90 mmHg, requiring treatment with vasopressors</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2009"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing Significant Ventricular Arrhythmia</title>
        <time_frame>Start (baseline) of first vernakalant infusion up to 24 hours after the last infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Participants treated with vernakalant IV in acute care and inpatient hospital settings
Vernakalant: Prescribed at the discretion of the physician in accordance with their usual practice</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Significant Ventricular Arrhythmia</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2009"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing Significant Atrial Flutter</title>
        <time_frame>Start (baseline) of first vernakalant infusion up to 24 hours after the last infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Participants treated with vernakalant IV in acute care and inpatient hospital settings
Vernakalant: Prescribed at the discretion of the physician in accordance with their usual practice</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Significant Atrial Flutter</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2009"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing Significant Bradycardia</title>
        <time_frame>Start (baseline) of first vernakalant infusion up to 24 hours after the last infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Participants treated with vernakalant IV in acute care and inpatient hospital settings
Vernakalant: Prescribed at the discretion of the physician in accordance with their usual practice</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Significant Bradycardia</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2009"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Are Converted to Sinus Rhythm for at Least One Minute</title>
        <time_frame>Up to 90 minutes after the start (baseline) of first infusion of vernakalant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Participants treated with vernakalant IV in acute care and inpatient hospital settings
Vernakalant: Prescribed at the discretion of the physician in accordance with their usual practice</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Are Converted to Sinus Rhythm for at Least One Minute</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1936"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hours after the last infusion of vernakalant IV or until discharge / end of medical encounter, whichever occurred earlier</time_frame>
      <desc>Health outcomes of interest (HOIs) were reported as defined in the study protocol section</desc>
      <group_list>
        <group group_id="E1">
          <title>All Participants</title>
          <description>Participants treated with vernakalant IV in acute care and inpatient hospital settings
Vernakalant: Prescribed at the discretion of the physician in accordance with their usual practice</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="2009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Significant hypotension</sub_title>
                <description>Significant hypotension defined as: symptomatic hypotension with systolic blood pressure (BP) &lt;90 mmHg, requiring treatment with vasopressors</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>significant ventricular arrhythmia</sub_title>
                <description>Significant ventricular arrhythmia:
Sustained VT with a ventricular heart rate &gt;120 bpm &gt;30 seconds or VT that required intervention or Torsade de Pointes with a duration of &gt;10 seconds, or Ventricular fibrillation of any duration</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Significant bradycardia</sub_title>
                <description>Significant bradycardia defined as: bradycardia requiring electrical pacing (temporary or permanent) or any other serious adverse event (SAE) reports involving bradycardia</description>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Significant atrial flutter with 1:1 conduction</sub_title>
                <description>Significant atrial flutter (AFL) defined as: AFL with 1:1 atrioventricular conduction of &gt;10 seconds duration and a ventricular rate of &gt;200 bpm</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Non-sustained ventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Non-sustained wide QRS complex tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2009"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2009"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="2009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="35" subjects_affected="35" subjects_at_risk="2009"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="2009"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Development</name_or_title>
      <organization>Correvio International</organization>
      <phone>+41 (0) 22 907 79 70</phone>
      <email>info@correvio.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

